Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials ; day:11 ; month:11 ; year:2020 ; pages:1-15
Advances in therapy ; (11.11.2020), 1-15
- Creator
-
Rabe, Klaus F.
Chalmers, James D.
Miravitlles, Marc
Kocks, Janwillem W. H.
Tsiligianni, Ioanna
Hoz, Alberto de la
Xue, Wenqiong
Singh, Dave
Ferguson, Gary T.
Wedzicha, Jadwiga
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-020-01528-2
- URN
-
urn:nbn:de:101:1-2020122218531023021153
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rabe, Klaus F.
- Chalmers, James D.
- Miravitlles, Marc
- Kocks, Janwillem W. H.
- Tsiligianni, Ioanna
- Hoz, Alberto de la
- Xue, Wenqiong
- Singh, Dave
- Ferguson, Gary T.
- Wedzicha, Jadwiga
- SpringerLink (Online service)
Other Objects (12)
Measuring disease activity in COPD: is clinically important deterioration the answer?
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Long-term outcomes following first short-term clinically important deterioration in COPD
Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
One‐year clinically important deterioration and long‐term clinical course in Japanese patients with COPD: a multicenter observational cohort study
Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference
Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire
Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care
Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study
Measuring disease activity in COPD: is clinically important deterioration the answer?
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Long-term outcomes following first short-term clinically important deterioration in COPD
Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
One‐year clinically important deterioration and long‐term clinical course in Japanese patients with COPD: a multicenter observational cohort study
Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference
Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire
Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care
Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study
Measuring disease activity in COPD: is clinically important deterioration the answer?
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
Long-term outcomes following first short-term clinically important deterioration in COPD
Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
One‐year clinically important deterioration and long‐term clinical course in Japanese patients with COPD: a multicenter observational cohort study
Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference
Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire
Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care